Business Context and Reporting Period
This Form 8-K reports on the results of iBio, Inc.'s 2017 Annual Meeting of Stockholders held on December 19, 2017. The company is incorporated in Delaware and is headquartered in New York, NY. As of the record date (November 16, 2017), 92,818,510 shares were entitled to vote, with 63,180,403 shares present in person or by proxy.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Stockholders voted on five proposals. Four were approved, and one was rejected:
- Proposal 1 (Election of Directors): Approved. John D. McKey, Jr. and Seymour Flug were elected as Class III directors for a three-year term.
- Proposal 2 (Auditor Ratification): Approved. CohnReznick LLP was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2018.
- Proposal 3 (Say-on-Pay): Approved. The advisory vote on executive compensation passed with 32,863,534 shares "FOR".
- Proposal 4 (Authorized Shares Increase): Approved. The number of authorized common shares was increased from 175 million to 275 million.
- Proposal 5 (Equity Incentive Plan Amendment): Not Approved. The proposal to increase shares authorized for issuance under the 2008 Omnibus Equity Incentive Plan from 15 million to 25 million failed to achieve a majority of shares present. Results: 30,670,650 "FOR", 4,385,920 "AGAINST", and 28,024,006 broker non-votes.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk highlighted by the voting results is the rejection of the equity plan amendment, which may limit the company's ability to issue new shares for employee compensation under the current plan limits until a new proposal is submitted and approved.
Key Facts for Investor Verification
- Verify the impact of the rejected Proposal 5 on the company's ability to grant equity incentives to employees and executives.
- Confirm the new authorized share count of 275 million following the approval of Proposal 4.
- Review the Proxy Statement (filed November 27, 2017) for detailed rationale behind the failed equity plan amendment.
- Note the significant number of broker non-votes (28,024,006) which impacted the total voting pool but did not count toward the "FOR" or "AGAINST" tallies for the failed proposal.